Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCHW) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Envoy Medical (COCHW) over the last 4 years, with Q3 2025 value amounting to $21.9 million.

  • Envoy Medical's Shares Outstanding (Diluted Average) rose 1737.85% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.9 million, marking a year-over-year increase of 1737.85%. This contributed to the annual value of $18.8 million for FY2024, which is 5282.51% up from last year.
  • Per Envoy Medical's latest filing, its Shares Outstanding (Diluted Average) stood at $21.9 million for Q3 2025, which was up 1737.85% from $21.4 million recorded in Q2 2025.
  • Over the past 5 years, Envoy Medical's Shares Outstanding (Diluted Average) peaked at $42.5 million during Q1 2022, and registered a low of $10.1 million during Q1 2023.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $19.2 million, with a median of $18.6 million in 2024.
  • In the last 5 years, Envoy Medical's Shares Outstanding (Diluted Average) tumbled by 7618.22% in 2023 and then surged by 8374.74% in 2024.
  • Envoy Medical's Shares Outstanding (Diluted Average) (Quarter) stood at $10.1 million in 2022, then increased by 21.46% to $12.3 million in 2023, then soared by 52.83% to $18.8 million in 2024, then increased by 16.29% to $21.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $21.9 million in Q3 2025, compared to $21.4 million in Q2 2025 and $21.3 million in Q1 2025.